Listen
ENSTILAR (calcipotriol, betamethasone), antipsoriatic
DERMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Nov 09 2017
Reason for request
Inclusion
- ENSTILAR, in a cutaneous foam form, has Marketing Authorisation in the topical treatment of psoriasis vulgaris in adults.
- Other medicinal products, with the same active ingredients, have Marketing Authorisation in a similar indication: DAIVOBET gel and ointment, XAMIOL gel.
- ENSTILAR has demonstrated its superiority compared with other fixed combinations of calcipotriol/betamethasone in ointment and gel forms with a modest effect based on the overall assessment of the investigator.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| minor |
- |
English version
Contact Us
Évaluation des médicaments
